Literature DB >> 20112742

[Identification of TGF-beta/Smads pathway in human prostate cancer cell lines and its significance].

Kai-jie Wu1, Guang-feng Zhu, Dong Zhang, Jin Zeng, Xin-yang Wang, Yan Xue, Lin-lin Zhang, Da-lin He.   

Abstract

OBJECTIVE: To determine the TGF-beta/Smads signal pathway in different human prostate cancer cell lines, and to explore the role of the TGF-beta/Smads pathway in the progression and metastasis of prostate cancer and its possible mechanisms.
METHODS: We detected the expressions of the key proteins involved in the TGF-beta/Smads pathway, TbetaR II, Smad2/3, p-Smad2 and Smad4, in prostate cancer cell lines LNCaP, PC-3, DU145, IF11 and IA8 with different metastatic potentials by Western blotting.
RESULTS: TbetaR II was expressed highly in PC-3, DU145, IF11 and IA8, but extremely lowly in LNCaP. Smad2/3 was highly expressed in all the cell lines with different intensity, while p-Smad2 only in PC-3 and DU145. The expression of Smad4 was detected in LNCaP, PC-3 and DU145, but not in IF11 and IA8.
CONCLUSION: The status of the TGF-beta/Smads pathway differs in the cell lines with different metastatic potentials, only active in PC-3 and DU145. The TGF-beta/Smads pathway may be involved in the invasion and metastasis of prostate cancer through altering the expressions of the key proteins in it.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20112742

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  2 in total

1.  Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration.

Authors:  BaoHan T Vo; Shafiq A Khan
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

2.  Expression pattern of p-Smad2/Smad4 as a predictor of survival in invasive breast ductal carcinoma.

Authors:  Nannan Liu; Dongxue Qi; Jing Jiang; Jihong Zhang; Chunyan Yu
Journal:  Oncol Lett       Date:  2020-01-13       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.